688578.SS
Strong BuyPremium GrowerAI neutralShanghai Allist Pharmaceuticals Co., Ltd. · Healthcare · China · $7.0B
CNY 111.58 +5.0% · close 30 Sep · scored 7 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
The Value score is 40, failing the eligibility threshold of 50. Despite strong EPS momentum, the quantitative valuation profile is insufficient for this screen.
ABOUT SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
Read
Shanghai Allist Pharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative oncology therapies. The company's flagship product, Furmonertinib, is a self-developed, third-generation EGFR inhibitor approved for the treatment of non-small cell lung cancer (NSCLC). Its competitive moat is anchored by strong clinical efficacy data, robust patent protection, and rapid market penetration supported by inclusion in China's National Reimbursement Drug List (NRDL).
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 791.0M | 2.0B | 3.6B | 5.2B | 87.2% | 6.1B | 6.9B | 8.3B | 26.4% |
| EPS (CNY) | 0.29 | 1.43 | 3.18 | 4.86 | 155.9% | 5.93 | 6.93 | 7.87 | 27.2% |
| Shares | 450.0M | 450.0M | 450.0M | 450.0M | 0.0% | 450.0M | — | — | — |
| Debt | 2.0M | 1.8M | 1.3M | 3.9M | 25.7% | 4.2M | — | — | — |
| Equity | 3.2B | 4.0B | 5.3B | 7.1B | 30.5% | — | — | — | — |
| Op CF | 91.6M | 674.6M | 1.6B | 2.3B | 193.7% | 2.7B | — | — | — |
| Inv CF | -404.2M | 92.8M | -1.8B | -2.0B | — | — | — | — | — |
| Fin CF | -3.7M | -2.2M | -295.0M | -363.0M | — | — | — | — | — |
Swung more than 57% of stocks we rank over the past year (46% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688578.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688578.SS | Shanghai Allist Pharmaceuticals Co., Ltd.(you) | $7.0B | 90 | Strong Buy |
| 9995.HK | RemeGen Co., Ltd. | $5.5B | 93 | Strong Buy |
| 3759.HK | Pharmaron Beijing Co., Ltd. | $7.1B | 81 | Strong Buy |
| 688336.SS | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd | $5.2B | 93 | Strong Buy |
| 1530.HK | 3SBio Inc. | $5.2B | 97 | Strong Buy |
| 6821.HK | Asymchem Laboratories (Tianjin) Co., Ltd. | $6.9B | 66 | Buy |
| 2315.HK | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | $3.8B | 72 | Buy |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $27.2B | 86 | Strong Buy |
| 300009.SZ | Anhui Anke Biotechnology (Group) Co., Ltd. | $2.1B | 82 | Strong Buy |
| 2142.HK | HBM Holdings Limited | $1.5B | 88 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 52.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.